In addition to the signals obtained by ligation of the TCR, T cells need additional, co-stimulatory signals to be activated. One such co-stimulatory signal is delivered when CD28 on T cells binds to CD80 or CD86 on antigen-presenting cells (APC). In the present study, we analyzed the ability of CD80 and CD86 to co-stimulate human T cells activated by superantigen. Using the Raji B cell lymphoma, which express similar levels of CD80 and CD86, it was found that T cell proliferation was mainly co-stimulated by CD80. To further characterize the consequences of this biased costimulatory dependency, we employed a well-defined system of transfected CHO cells expressing human MHC class II together with CD80, CD86 or CD80 and CD86. Proliferation of freshly prepared CD4 ⍣ T cells required the presence of either CD80 or CD86. However, IL-2 production reached only suboptimal levels in the presence of CD86 but optimal levels with CD80. To analyze IL-2 transcriptional activity in CD80 and CD86 co-stimulated T cells we used Jurkat T cells transfected with luciferase reporter gene constructs. CD80 induced higher levels of IL-2 promoter-enhancer activity compared to CD86. Furthermore, the activity of transcription factors regulating the IL-2 promoter-enhancer region including activation protein-1, CD28 response element and nuclear factor κB were 4-8 times higher after CD80 compared to CD86 ligation. Our results suggest that the eventual appearance of CD80 on recently activated CD86 ⍣ APC is important for the superinduction of IL-2 production and to support vigorous T cell proliferation.
Introduction
Activation of T cells into cytokine production and cell proliferation (1,2) requires not only that the TCR is engaged with antigen presented in the context of MHC molecules on an antigen-presenting cell (APC), but also that the APC expresses additional molecules which can deliver co-stimulatory (or second) signals to the T cell (3) (4) (5) . Examples of such costimulatory molecules are CD80, CD86, ICAM-1 and CD58 (LFA-3) (5-12). CD80 (BB1, B7-1) and CD86 (B70, B7-2) provide the major co-stimulatory signals by engaging CD28 on T cells. The expression of CD80 and CD86 is up-regulated by stimuli such as cytokines (13) , ligation of CD40 (14) , engagement of surface Ig (15) or by bacterial components, such as lipopolysaccharide (15) . However, the expression kinetics differ markedly between CD80 and CD86 during activation (12, 15, 16) . Whereas CD86 is expressed at low Correspondence to: M. Dohlsten Transmitting editor: G. Klein Received 20 October 1997, accepted 6 January 1998 levels on resting APC and is rapidly up-regulated during activation, CD80 is usually absent on resting APC and cannot be detected until after 24 h of activation (15) . This has led to the suggestion that CD86 is the major co-stimulatory molecule during the initiation of an immune response, whereas CD80 may act during the latter phase, possibly contributing to the maintenance of immune responses (17) . Furthermore, it has been suggested that qualitatively different signals are delivered through CD28 by CD80 as compared to by CD86 ligation (18, 19) . Others, however, have reported that CD80 and CD86 equally co-stimulate proliferation, cytokine production and generation of effector T cells (20) . Thus, it is still not clear whether CD80 and CD86 show intrinsic differences in activating CD28 ϩ T cells.
In the present study, we compared the impact of CD80 versus CD86 in superantigen-mediated activation of human T cells. First, the relative importance of the two molecules was examined by using mAb to block co-stimulation by Raji, a Burkitt's lymphoma B cell line (B-LCL) which express similar levels of both CD80 and CD86. To more carefully investigate the consequences of CD80 and CD86 ligation on T cell activation, we employed a well-defined system of CHO transfectants expressing human HLA-DR, CD80 and CD86 (21) (22) (23) . We found that CD80-mediated co-stimulation induced stronger IL-2 transcription and IL-2 production compared to CD86. To determine whether this observation reflected a differential involvement on transcription factors regulating the IL-2 promoter, we determined the induction of CD28 response element (CD28RE), activation protein-1 (AP-1), nuclear factor κB (NF-κB) and nuclear factor of activated T cells (NF-AT) transcriptional activity in Jurkat T cells co-stimulated by CD80 or CD86.
Methods

Medium and reagents
RPMI 1640 medium (Gibco, Middlesex, UK) supplemented with 2 mM L-glutamine (Gibco), 0.01 M HEPES (ICN Biomedicals, Costa Mesa, CA), 1 mM NaHCO 3 (Biochrom, Berlin, Germany), 0.1 mg/ml gentamycin sulfate (Biological Industries, Kibbutz Beit Haemek, Israel), 1 mM sodium pyruvate (JRH Biosciences Industries, Lenexa, KS) and 10% fetal bovine serum (Hyclone, Logan, UT) was used as complete medium for cell cultures.
Mouse anti-human CD4-phycoerythrin, CD80-phycoerythrin and CD3-phycoerythrin were all purchased from Becton Dickinson (San Jose, CA). Mouse anti-human CD3-FITC was purchased from Dakopatts (Glostrup, Denmark). Mouse mAb reacting with human CD80 (BB1), human CD86 (IT2.2) and CD86-phycoerythrin (IT2.2) were purchased from PharMingen (San Diego, CA). Human CTLA-4-Ig was a kind gift from Peter S. Linsley (Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA) (24) .
The staphylococcal enterotoxin A (SEA)-Fab fusion protein (SEA fp ), consists of SEA fused to the C-terminus of the heavy chain of a Fab reactive with the human colon carcinoma antigen C215 (25) . The fusion protein was expressed as a bicistronic transcript unit and purified to homogeneity as previously described (26) . The recombinant SEA and SEE proteins (27) were expressed in Escherichia coli, and purified to homogeneity as described elsewhere (28) .
Cell lines
Chinese hamster ovary (CHO) K1 cells transfected with cDNA encoding the human HLA-DR4 (DR) under the control of a human cytomegalovirus (hCMV) promoter (29) (provided by D. Sansom, Bath, UK) (30) were transfected with human cDNA encoding the CD80 gene (gift from B. Dupont, Sloan Kettering Institute, New York) or the CD86 gene (31) (gift from L. Lanier and M. Azuma, Department of Human Immunology, DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA). The cDNA for the CD80 coding region was expressed under the control of a hCMV immediate early promoter in the vector pEE6 hCMV (a gift from Dr C. Bebbington, Celltech, Slough, UK). The cDNA for the human CD86 coding region was expressed under the control of a human SV40 early promoter in the vector pLXSN (32) . CHO-K1 cells were transfected by electroporation to create either CHO-DR single transfectants, CHO-DR-CD80 or CHO-DR-CD86 double transfectants as well as CHO-DR-CD80-CD86 triple transfectants. Transfectants were selected for positive expression 48 h after electroporation by FACS sorting, and were thereafter repeatedly sorted to obtain high expressing cell lines and finally cloned to obtain a homogenous population. The transfectants expressed similar amounts of CD80 and CD86, and were routinely analyzed for expression of DR, CD80 and CD86, according to a standard setting on a FACStar Plus flow cytometer (Becton Dickinson, Mountain View, CA) supported by CellQuest software. The CHO transfectants were irradiated (20000 rad) before used as APC.
SEA-reactive T cell lines were established by culturing peripheral blood leukocytes (PBL) from healthy donors with SEA for 7 days, after which the cells were expanded in IL-2. The T cell lines were maintained in IL-2-containing medium and were re-stimulated once a week with SEA presented by the B cell lymphoma BSM (33) . The results in Fig. 1 (B) represents a T cell line that had been maintained 4 weeks in vitro and re-stimulated 10 days before the experiment was performed.
The human Jurkat leukemic CD4 ϩ T cell clone (gift from Dr C. L. Verweij, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam and Academic Hospital Leiden, Netherlands) was maintained in complete culture medium.
Raji was obtained from ATCC (Rockville, MD), and was grown in complete medium and used as APC following irradiation (20000 rad) in proliferation assays.
All cell lines were tested to be Mycoplasma free.
Preparation of CD4 ϩ T cells PBL were isolated from buffy coats obtained from healthy blood donors by density centrifugation over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) as previously described (34) . T cells were enriched by separation over a gelatin column followed by positive selection of the CD4 ϩ T cells by MACS (Miltenyi Biotec, Sunnyvale, CA) according to the manufacturer's description. The purity of the separated cells were routinely checked by FACS analyses and were 99% CD4 ϩ cells.
Measurement of T cell activation
SEA-reactive human T cell lines (10 5 presented by CHO transfectants (10 4 ) for 24 h after which the amount of IL-2 was determined by ELISA.
DNA transfection and luciferase reporter gene assay
The plasmid constructs used for studies of the IL-2 promoter activity includes a single copy of SV40 enhancer element in combination with an IL-2 promoter-enhancer region linked to the firefly luciferase reporter gene. Human IL-2 promoterenhancer elements (-500 to ϩ60) were subcloned from plasmid SV-IL-2-CAT into pGL2 luciferase vector (Promega, Madison, WI). Briefly, the -500 to ϩ60 fragment was prepared by PCR using primers that created a 5Ј XhoI site and a 3Ј HindIII site. The AP-1 luciferase reporter gene was driven by the rat prolactin minimal promoter (RPP, -36 to ϩ37) under the control of four copies of the human AP-1 site (35), provided by M. Rincó n and R. A. Flavell (Section of Immunobiology, Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT). Plasmids containing 2ϫNF-κB, 3ϫNF-AT or 4ϫCD28RE enhancer fragments was also constructed as luciferase reporter gene constructs (17) . Jurkat T cells were transfected by electroporation in an electro cell manipulator (BMX 600, San Diego, CA). Briefly, exponentially growing Jurkat T cells (4ϫ10 7 cells/ml) were mixed with the different plasmid luciferase reporter gene constructs (10 µg plasmid DNA) in complete medium at 4°C. The cells were electroporated using 130 V and 3100 µF capacitance, and cultured for 24 h before being co-cultured in 24-well plates (Nunc) with the different CHO transfectants in the absence or presence of 100 ng/ml SEE. After 4 h (NF-κB) or 8 h (IL-2 promoter, CD28RE, AP-1 and NF-AT) of culture, Jurkat T cells were harvested, washed twice in PBS and treated with reporter lysis buffer (Promega) for 5 min on ice. The culture periods were based on kinetic experiments which showed optimal induction of luciferase activity in NF-κB-driven constructs after 4 h, and for CD28RE, AP-1 and NF-AT driven constructs after 8 h (17 and data not shown).
Lysates were centrifuged and the luciferase content was measured in a luminometer (MicroLumat LB 96 P; Berthold, Bad Wildbad, Germany) for 2 min in the presence of luciferase assay reagent (Promega). Background values were subtracted from each sample and experimental values were expressed as relative activity compared to extracts from unstimulated cells.
Results
Co-stimulation by Raji is dominated by CD80, despite equal levels of CD80 and CD86 We first investigated the relative roles of CD80 and CD86 on T cell activation by a typically activated APC, i.e. Raji., a Burkitt's lymphoma B cell line (B-LCL). FACS analysis of Raji cells showed that they expressed high levels of HLA-DR, and equal levels of CD80 and CD86 (Fig. 1A) . To analyze the contributions of CD80 versus CD86 on co-stimulation, a human SEA-reactive T cell line was stimulated with SEA presented by Raji cells in the presence of titrated amounts of mouse mAb towards human CD80, CD86, irrelevant mouse IgG or the fusion protein hCTLA-4-Ig. Figure 1B shows the proliferative response at a mAb/CTLA-4-Ig concentration of 0.2 µg/ml. CTLA-4-Ig and anti-CD80 (alone or together with anti-CD86) efficiently inhibited the proliferative T cell response, whereas anti-CD86 alone inhibited the response only marginally. No further inhibition was seen at higher anti-CD86 concentrations (up to 5 µg/ml). Similar results were also obtained using BSM (33) (another B-LCL) as APC (data not shown).
It has previously been reported that the anti-CD80 mAb (BB1) and anti-CD86 mAb (IT2.2) used in this study have blocking capacity (36) (37) (38) . However, to ascertain that the mAb specifically blocked CD80 and CD86 in the present experiments, we analyzed the IL-2 production by Jurkat T cells stimulated with SEE presented by the CHO transfectants CHO-DR-CD80, CHO-DR-CD86 and CHO-DR-CD80-CD86 (21) (22) (23) in the presence of the anti-CD80 and anti-CD86 mAb. The expression of DR, CD80 and CD86 by these transfectants was routinely checked by FACS to confirm that the transfectants expressed similar cell surface levels of the proteins. As shown in Fig. 2 , the mAb specifically inhibited co-stimulation by CD80 and CD86 respectively. Furthermore, in conformity with the experiments using Raji as APC, presentation by CHO-DR-CD80-CD86 was not inhibited by anti-CD86 alone, but was strongly inhibited by anti-CD80. Thus, similar to the T cell line stimulated by Raji, Jurkat T cells stimulated by CHO transfectants were preferentially co-stimulated by CD80. Freshly isolated CD4 ϩ T cells are preferentially co-stimulated by CD80
The previous experiments were performed with T cell lines and Jurkat T cells. It could be argued that these cells do not have the same co-stimulatory demands as primary T cells. Therefore, we investigated the ability of the different transfectants to stimulate freshly isolated CD4 ϩ T cells from human peripheral blood. The cells were co-cultured with SEA fp and either CHO-DR, CHO-DR-CD80, CHO-DR-CD86 or CHO-DR-CD80-CD86 after which T cell proliferation and IL-2 production was measured (Fig. 3) . Similar to the SEA-reactive T cell line and the Jurkat T cells, the proliferation as well as the IL-2 production by the freshly prepared CD4 ϩ T cells exhibited a biased dependency on CD80. No difference in IL-2 production was seen between CD4 ϩ T cells co-stimulated by CD80 compared to by CD80 together with CD86. The T cell proliferation, on the other hand, was augmented when T cells were co-stimulated by both CD80 and CD86. The proliferative response of freshly prepared CD8 ϩ T cells displayed a similar biased dependence on CD80 as did the CD4 ϩ T cells (data not shown).
CD80 ligation induces more strongly IL-2 promoter transcriptional activity in Jurkat T cells
Based on the findings that both T cell lines, Jurkat T cells and freshly isolated CD4 ϩ T cells were preferentially costimulated by CD80, we wanted to analyze the effects of CD80 and CD86 co-stimulation on IL-2 gene transcriptional activity. The critical regulatory and inducible activity of the IL-2 enhancer-promoter region is contained within 300 bp immediately up-stream of the start site (30, 39, 40) . This region has been shown to contain binding sequences for several defined transcription factors involved in the regulation of the IL-2 gene, including NF-κB, CD28RE, AP-1 and NF-AT.
Jurkat T cells were transiently transfected with the human IL-2 enhancer-promoter region fused to the luciferase reporter gene. The transfected cells were stimulated with SEE presented by the different CHO transfectants, after which the transcriptional activity of the IL-2 promoter as well as the IL-2 production was determined. As shown in Fig. 4A , stimulation with SEE in the absence of CD80 or CD86 resulted in IL-2 promoter transcriptional activity comparable to controls without SEE. CD80 co-stimulation resulted in a high transcriptional activity that was Ͼ2 times stronger than after CD86 costimulation. In the presence of both co-stimulatory molecules, an additive effect on transcriptional activity was seen. The IL-2 production (Fig. 4B ) displayed the same pattern as did the transcriptional activity.
Preferential induction of NF-κB, AP-1 and CD28RE driven transcription by CD80
To further dissect the impact of co-stimulation on IL-2 gene transcription, we analyzed activation of the different transcrip- tion factors reported to bind to the IL-2 promoter. Luciferase reporter gene constructs containing tandem repeats of binding elements for NF-κB, NF-AT, AP-1 or CD28RE (17) were used to transiently transfect Jurkat T cells, which were then cocultured with the different CHO transfectants in the absence (unstimulated cells) or presence of SEE. CD28RE, AP-1 and NF-κB were strongly induced by co-stimulation with CD80, exhibiting 4-to 8-fold higher activities compared to costimulation with CD86. No activity was detected in Jurkat T cells stimulated by SEE and CHO-DR cells alone or in cultures with Jurkat T cells and the different CHO transfectants in the absence of SEE (Fig. 5A-C) . Generally, an additive effect on the transcriptional activity was observed when Jurkat were co-stimulated by the triple transfectant CHO-DR-CD80-CD86. Interestingly, Jurkat T cells showed a significant induction of NF-AT transcriptional activity when stimulated by SEE and cells expressing DR only (Fig. 5D) . Furthermore, the difference between CD80, CD86 or CD80 together with CD86 to induce NF-AT was less pronounced compared to the effects on NF-κB, AP-1 and CD28RE.
Thus, AP-1, CD28RE and NF-κB, that previously have been reported to be dependent on CD28-mediated co-stimulation (35) , are strongly induced by co-stimulation with CD80 and only marginally by CD86.
Discussion
The two CD28 ligands CD80 and CD86 differ by means of expression kinetics and binding to CD28. This, together with other functional studies, have led to the suggestion that CD80 and CD86 play unique roles during an immune response (17) (18) (19) . In the present report, we have investigated the ability of CD80 and CD86 to co-stimulate T cells responding to superantigen, using different types of T cells together with B-LCL as well as transfected CHO cells as APC. We found that the T cells were preferentially co-stimulated by CD80 rather than by CD86. Analysis of the transcription factors regulating the IL-2 gene suggested that one explanation for the biased co-stimulatory ability may reside at the level of induction of the transcription factors NF-κB, AP-1 and CD28RE.
A number of studies have investigated the relative importance of CD80 and CD86. However, no consensus has been reached as to whether they possess distinct functions. As to proliferative T cell responses, investigators employing freshly prepared APC have generally reported preferential co-stimulation by CD86 (31, 41) , with some exceptions (42, 43) . Possibly, this is due to the dominant expression of CD86 over CD80 on APC populations such as bulk PBL or freshly isolated monocytes or dendritic cells (13) (14) (15) . On the other hand, investigators using accessory cells that express similar levels of CD80 and CD86 (e.g. Epstein-Barr virus-transformed B cells or transfected cells) have reported conflicting results. Some of these studies suggest that there is a biased dependency on either CD80 or CD86, whereas others show that CD80 and CD86 display similar ability to co-stimulate T cells (20, 44) . One explanation for the different results could reside in the nature of the stimulus. In our experiments, in which a relatively low dose of SEA was used (10 pM), anti-CD80 and anti-CD86 mAb exhibited differential inhibitory capacities on T cell activation. Anti-CD80 mAb inhibited almost completely (90%) T cell activation induced by SEA-presenting Raji cells, whereas anti-CD86 mAb only marginally inhibited T cell activation. However, a combination of anti-CD80 and anti-CD86 mAb was slightly more effective than anti-CD80 mAb alone, suggesting that the presence of CD86 may act to augment CD80 driven co-stimulation. Interestingly, in the present experimental system we noted that the impact of blocking CD80 and CD86 was less at higher SEA doses (data not shown), suggesting that a stronger signal 1 can partially overcome the dependence of the CD28 signal, perhaps via a redundant signal transduction through other co-stimulatory molecules. Still, we argue that it is more relevant to focus on suboptimal stimulation, inasmuch as this possibly reflects better the in vivo physiological situation.
To be able to more carefully investigate the consequences of CD80 and CD86 ligation on T cell activation, we employed an experimental system based on CHO cells transfected with DR together with either CD80 or CD86, or CD80 together with CD86 (21) (22) (23) . We found that human CD4 ϩ T cells responded only marginally to TCR engagement by superantigen presented by CHO-DR and that co-stimulation with CD80 induced a profound IL-2 production and T cell proliferation. CD86 could co-stimulate both IL-2 production and proliferation, but only suboptimally. As previously reported (45) , co-expression of CD80 and CD86 resulted in an additive effect on T cell proliferation. It has been suggested that CD86 preferentially co-stimulates T h 2 cytokines (46). However, we could not detect either IL-4 nor IL-10 in supernatants from stimulated CD4 ϩ T cells (data not shown).
In order to investigate the influence of CD80 and CD86 ligation on IL-2 transcription, we stimulated Jurkat T cells, transiently transfected with luciferase reporter gene constructs with SEE presented by the CHO transfectants. IL-2 gene expression seems to require the action of several signal transduction pathways that integrate at the level of the nuclear transcription factors (47) . Many of these transcription factors have been shown to regulate the IL-2 gene, including AP-1 (21), NF-κB (48), NF-AT (49), Oct-1 (21), and CD28RE (50) . Previous studies have shown that CD80 co-stimulation of superantigen engaged T cells, augmented T cell activation by enhancing IL-2 transcription, IL-2 mRNA stability and IL-2 receptor α-and γ-chain expression (31, 51) . In the present study, we could confirm that both CD80 and CD86 costimulation induced IL-2 gene transcription. However, CD86 induced a 2-to 3-fold lower level of transcriptional activity and IL-2 production compared to CD80. This suggests that the differences between CD80 and CD86, with respect to IL-2 production, may reside at the level of transcriptional regulation of the IL-2 promoter. Moreover, CD80 induced strong AP-1 and NF-κB transcriptional activity, moderate CD28RE activity, and a significant but low increase in NF-AT activity. In contrast, CD86 co-stimulated at relatively 4-to 8-fold lower levels of AP-1, NF-κB and CD28RE transcriptional activity. Mutational analyses of the intact IL-2 promoter have previously demonstrated that the CD28RE sequence is crucial for CD80-induced IL-2 transcription. The relatively modest induction of CD28RE in CD80 co-stimulated cells seen in this and other papers (17, 52) supports the notion that CD28RE binding proteins acts in a cis context with nuclear factors binding to flanking sequences, e.g. AP-1, to superinduce IL-2 transcription. Co-expression of both CD80 and CD86 resulted in an additive induction of all the transcription factors in SEE stimulated Jurkat T cells. These data suggest that CD80 induces a quantitatively stronger signal along the CD28 signal transduction pathway, but that no major qualitative differences in the regulation of nuclear factors controlling the IL-2 promoter are induced by CD80 compared to CD86. Interestingly, the induction of the transcription factor NF-AT was not as dependent on co-stimulation as were AP-1, NF-κB and CD28RE. This confirms earlier results that have primarily linked NF-AT activation to the TCR signal transduction pathway (53) . NF-AT proteins have been shown to be cytosolic in quiescent T cells, but that they translocate to the nucleus in TCR-activated cells and combine with AP-1 protein to form a functional transcription factor complex (53) . The nuclear translocation of NF-AT proteins is controlled by calciumdependent signals which are most often elicited after TCR ligation (54) . The present finding showing strong induction of NF-AT activity by SEA/HLA-DR triggered T cells is compatible with engagement of TCR, Ca 2ϩ mobilization and thus NF-AT activation (53, 55) . This is to our knowledge the first study that has compared the influence of CD80 and CD86 on the induction of IL-2 gene regulation. Based on the kinetics of CD80 and CD86 expression (15, 45) and the present data, we suggest that CD86 plays a role in the early phase of a T cell response by inducing suboptimal IL-2 production which drives an autocrine clonal T cell expansion. However, a transition into a vigorous and long-lasting paracrine immune response requires participation by CD80, which is superior in the induction of AP-1, NF-κB and CD28RE, activity resulting in superinduction of IL-2 production.
